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Abstract
Background: The deregulation of E-cadherin has been considered as a leading cause of hepatocellular carcinoma
(HCC) metastasis. BCL6 corepressor-like 1 (BCORL1) is a transcriptional corepressor and contributes to the repression
of E-cadherin. However, the clinical significance of BCORL1 and its role in the metastasis of HCC remain unknown.
Methods: Differentially expressed BCORL1 between HCC and matched tumor-adjacent tissues, HCC cell lines and
normal hepatic cell line were detected by Western blot. The expression of BCORL1 was altered by siRNAs or
lentivirus-mediated vectors. Transwell assays were performed to determine HCC cell invasion and migration.
Results: Increased expression of BCORL1 protein was detected in HCC specimens and cell lines. Clinical association
analysis showed that BCORL1 protein was expressed at significant higher levels in HCC patients with multiple tumor
nodes, venous infiltration and advanced TNM tumor stage. Survival analysis indicated that high expression of BCORL1
protein conferred shorter overall survival (OS) and recurrence-free survival (RFS) of HCC patients. Multivariate Cox
regression analysis disclosed that BCORL1 expression was an independent prognostic marker for predicting
survival of HCC patients. Our in vitro studies demonstrated that BCORL1 prominently promoted HCC cell
migration and invasion. Otherwise, an inverse correlation between BCORL1 and E-cadherin expression was
observed in HCC tissues. BCORL1 inversely regulated E-cadherin abundance and subsequently facilitated
epithelial-mesenchymal transition (EMT) in HCC cells. Notably, the effect of BCORL1 knockdown on HCC cells
was abrogated by E-cadherin silencing.
Conclusions: BCORL1 may be a novel prognostic factor and promotes cell migration and invasion through
E-cadherin repression-induced EMT in HCC.
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Background
Hepatocellular carcinoma (HCC) is the 5th most fre-
quent malignancy and 3rd most common cause of
cancer mortality in the world [1]. Due to high infection
rate of hepatitis B virus (HBV), HCC has been consid-
ered as a serious health problem in China [2]. Postopera-
tive recurrence and metastasis is the leading cause of
poor prognosis for HCC patients [3]. E-cadherin, an im-
portant member of cadherin family, functions as a key
factor in regulation of epithelial cell-to-cell adhesion [4].
Numerous studies have reported that impaired expres-
sion and/or dysfunction of E-cadherin leads to loss of
epithelial phenotype and promotes cell migration and
invasion in human cancer [5]. Furthermore, loss
expression of E-cadherin contributes to epithelial-
mesenchymal transition (EMT), which is a main cause
of tumor metastasis [6]. It has been demonstrated that
reduced expression of E-cadherin was correlated with
invasion and metastasis of various human cancers including
HCC [7]. Mechanistically, transcriptional repressors includ-
ing Snail, Slug, Twist, Zinc finger E-box-binding homeobox
1/2 (ZEB1/2) and C-terminal-binding protein (CtBP) are
involved in the regulation of E-cadherin expression [8, 9].
BCL6 corepressor-like 1 (BCORL1) is a recently
identified transcriptional corepressor [10]. Co-immuno
precipitation indicates that BCORL1 interacts with class
II histone deacetylases, such as HDAC4, HDAC5 and
HDAC7 [10]. Furthermore, BCORL1 represses the ex-
pression of E-cadherin via locating on the E-cadherin
promoter. Otherwise, BCORL1 interacts with the amino
terminus of CtBP via the PXDLS motif and suppresses
the transcription of E-cadherin [10]. It is conceivable,
therefore, that BCORL1 might promote tumor metasta-
sis. Yasushi Totoki et al. validated that BCORL1- E74-
like factor 4 (ELF4) was a somatic fusion transcripts
generated by rearrangements through sequencing
analysis of the HCC and matched non-cancerous liver
tissues [11]. Compared with the expression of wild-type
BCORL1 and ELF4 gene in non-tumor tissues, in-
creased expression of fusion transcripts was confirmed
in HCC tissues by quantitative reverse transcription-
PCR (qRT-PCR) [11]. However, in HCC, the clinical
significance of BCORL1 and its functional role remain
poorly investigated.
This study confirms that increased expression of
BCORL1 is observed in HCC tissues and cell lines. Ele-
vated expression of BCORL1 is evidently associated
with poor prognostic features and reduced survival of
HCC patients. BCORL1 promotes the invasive behavior
of HCC cells and inversely regulates the abundance of
E-cadherin in HCC cells. Mechanistically, our data indi-
cate that BCORL1 promotes the invasive ability of
HCC cells by suppressing E-cadherin and subsequently
facilitating EMT.
Methods
Cell culture and transfection
Human HCC cells (HepG2, Hep3B, HCCLM3 and
MHCC97H) and immortalized liver cell line (LO2) were
obtained from the Institute of Biochemistry and Cell Biol-
ogy, Chinese Academy of Science, China. Cells were main-
tained in Dulbecco’s Modified Eagle Medium (DMEM,
Gibco, Grand Island, NY, USA), which was supplemented
with 10 % fetal bovine serum (FBS, Gibco), 100 μg/ml
penicillin, and 100 μg/ml streptomycin (Sigma, St-Louis,
MO, USA), at 37 °C in a 5 % CO2 incubator.
A specific BCORL1 siRNA (5′-AGC CCU CAG CCU
CUG CCA CG-3′), E-cadherin siRNA (5′-CAG ACA
AAG ACC AGG ACU A-3′) and a nonspecific duplex
oligonucleotide as a negative control were synthesized
by Sangon Biotech (Shanghai) Co., Ltd. (Shanghai,
China). A predesigned siRNA directed against human
BCORL1 (BCORL1 siRNA-1) was purchased from
Qiagen (SI00311437; Shanghai, China). The siRNAs
mentioned above were transfected into HCC cells
using Lipofectamine 2000 following the manufacturer’s in-
structions (Invitrogen, Carlsbad, CA, USA). ORF lentiviral
expression clone (EX-W1876-Lv105-5) for BCORL1 was
purchased from Genecopoeia (Guangzhou, China). Lenti-
virus packaging and transduction were performed using
Lenti-Pac HIV Expression Packaging Kit (HPK-LvTR-20,
Genecopoeia) following manufacturer’s instructions.
In vitro migration, invasion and BrdU incorporation assays
The migration and invasion of HCC cells were measured
using 24-well Transwell plates (8-μm pore size, Corning,
NY, USA) as previously described [12]. For migration
assays, 5 × 104 cells were suspended in 200 μL serum
reduced DMEM medium and added into the upper
chamber with a non-coated membrane. For invasion
assays, chamber inserts were coated with Matrigel (BD
Biosciences, Franklin Lakes, NJ, USA) at 1:7 dilutions.
For the proliferation assay, HCC cells were seeded into
96-well plates at 5000 cells per well for 24 h and assessed
using a Cell Proliferation ELISA, BrdU (5-bromodeoxyuri-
dine) (chemiluminescent) (Roche, USA) as previously
described [13].
Patients and follow-up
HCC specimens and matched tumor-adjacent tissues
were obtained from 86 adult patients, who underwent
surgical resection of primary HCC between 2006 and
2008 at the First Affiliated Hospital of Xi’an Jiaotong
University. All samples were used after obtaining in-
formed consent. Patients that met the following criteria
were included: (a) confirmed pathologic diagnosis, (b)
no preoperative chemotherapy or radiotherapy, (c) no
distant metastases, (d) curative liver resection, and (e)
complete clinical-pathologic and follow-up data. Tumor
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differentiation level was assessed using Edmondson-
Steiner grading. The TNM stage of HCC was deter-
mined based on the guide of the 6th International Union
Against Cancer/American Joint Committee on Cancer
(UICC/AJCC). The clinicopathological data are shown in
Table 1.
The follow-up data were collected by the end of
December 2013 (with a median follow-up time of
35.5 months). Primary endpoints included the time
to recurrence and overall survival. The date of resection
to the date of tumor recurrence diagnosis was defined as
the time to recurrence. The duration between the date of
resection and the date of death or last follow-up was
calculated as the overall survival. This study was approved
by the Ethics Committee of the Xi’an Jiaotong University.
qRT-PCR
qPCR primer against to Homo sapiens E-cadherin
(NM_004360.2; HQP023466) and GAPDH (NM_0020
46.3; HQP006940) were purchased from Genecopoeia
(Guangzhou, China). The PCR amplification of the E-
cadherin and GAPDH mRNAs was performed accord-
ing the instruction of ABI PRISM 7300 Sequence
Detection System (Applied Biosystems, Foster City,
CA, USA) and the SYBR® Premix Ex Taq™ ii (Perfect
Real Time) Kit (Takara Bio, Shiga, Japan), as previous
described [14].
Western blot analysis
Proteins from lysed cells were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose membranes
(Bio-Rad, Hercules, CA, USA). Nonspecific binding sites
were blocked with 5 % BSA in TBST for 60 min at room
temperature. Blots were incubated with BCORL1 (PA5-
24333, Thermo Fisher Scientific Pierce, Waltham, MA,
USA), E-cadherin (24E10, #3195; Cell Signaling, Beverly,
MA, USA) or GAPDH (G8140; US Biological, Swamps-
cott, MA, USA) antibodies overnight at 4 °C. The mem-
branes were then incubated with horseradish peroxidase
(HRP)-conjugated sheep anti-mouse or donkey anti-rabbit
secondary antibodies (Bio-Rad, Hercules, CA, USA) di-
luted at 1:10000, and detected using the Western Blotting
Luminol Reagent (sc-2048, Santa Cruz, CA, USA) [15].
Immunohistochemical staining
Paraformaldehyde-fixed paraffin sections were used to per-
form the immunohistochemistry. BCORL1 (Thermo Fisher
Scientific Pierce) and E-cadherin (Cell Signaling) antibodies
at a dilution 1:100 were used in immunohistochemistry
Table 1 Clinicopathological correlation of BCORL1 expression in HCC
Clinicopathologic features n BCORL1 P
High expression (n = 43) Low expression (n = 43)
Age (y) ≤50 34 20 14 0.186
>50 52 23 29
Sex Male 76 37 39 0.501
Female 10 6 4
HBsAg No 12 7 5 0.534
Yes 74 36 38
Serum AFP level (ng/mL) ≤20 26 14 12 0.639
>20 60 29 31
Tumor size (cm) ≤5 39 18 21 0.516
>5 47 25 22
No. of tumor nodules 1 71 31 40 0.011*
≥2 15 12 3
Cirrhosis Absent 20 7 13 0.126
Present 66 36 30
Venous infiltration Absent 41 15 26 0.018*
Present 45 28 17
Edmondson-Steiner grading I+II 65 30 35 0.209
III+IV 21 13 8
TNM tumor stage I+II 64 28 36 0.048*
III+IV 22 15 7
HCC hepatocellular carcinoma, HBV hepatitis B virus, AFP alpha-fetoprotein, TNM tumor-node-metastasis. *Statistically significant
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with streptavidin peroxidase conjugated (SP-IHC) method.
Detailed procedures of immunohistochemistry were per-
formed as previous reported [16]. The percentage of posi-
tive tumor cells was scored according to the following
criteria: 0, less than 10 %; 1, 10–30 %; 2, 31–50 %; 3, more
than 50 %.
Immunofluorescence
The primary E-cadherin antibody (Cell Signaling) was
used in the immunofluorescence assays. The secondary
antibody was an Alexa Fluor–conjugated IgG (Invitrogen,
Carlsbad, CA, USA). Immunofluorescence was performed
as previous reported [15].
Statistical analysis
All statistical analyses were performed using the SPSS
statistical package for Windows Version 13 (SPSS, Chicago,
IL, USA) or GraphPad Prism 5 software (GraphPad Soft-
ware, Inc, San Diego, CA, USA). The quantitative data were
compared between groups using the Student’s t-test or
ANOVA. Categorical data were analyzed using the Pearson
chi-squared test. The Kaplan-Meier method and log-rank
test were used to compare the cumulative recurrence and
survival rates. The independent factors influencing the sur-
vival and recurrence of HCC patients were determined
using the Cox proportional hazards model. Correlation
analysis was tested by the Pearson’s correlation coeffi-
cient. A value of P < 0.05 was considered to be statisti-
cally significant.
Results
Expression of BCORL1 in clinical specimens and HCC cells
Initially, 86 pairs of HCC tissues and matched noncan-
cerous tissues were subjected to immunoblotting to
detect the protein level of BCORL1. As indicated in
Fig. 1a, the level of BCORL1 protein in HCC tissues was
significantly higher as compared with that in matched
tumor-adjacent tissues (P < 0.05). Furthermore, the expres-
sion of BCORL1 protein was determined by Western blot
in a normal hepatic cell line (LO2) and a panel of HCC cell
lines (HepG2, Hep3B, MHCC97H and HCCLM3). Our
data disclosed that BCORL1 protein levels in HCC cell lines
were significantly up-regulated compared with that in LO2
(P < 0.05, Fig. 1b). Otherwise, the levels of BCORL1 protein
in HCC cell lines (MHCC97H and HCCLM3) with high
metastatic ability were evidently higher than those in HCC
cell lines (HepG2 and Hep3B) with low metastatic ability
(P < 0.05, Fig. 1b). On the contrary, E-cadherin mRNA was
expressed at a significant lower level in HCC cell lines, es-
pecially in high invasive cell lines (P < 0.05, Fig. 1c). There-
fore, our results indicate that BCORL1 is overexpressed in
HCC specimens and cell lines.
Clinical significance of BCORL1 expression in HCC cases
The expression of BCORL1 was divided into low expres-
sion group (n = 43) and high expression group (n = 43)
based on its cutoff value, which was defined as the median
value of the cohort of patients tested. The correlation
between the expression of BCORL1 and clinicopathologic
features of HCC patients was summarized in Table 1. By
statistical analysis, increased level of BCORL1 was signifi-
cantly correlated with multiple tumor nodes (P = 0.011),
venous infiltration (P = 0.018) and advanced tumor-node-
metastasis (TNM) tumor stage (P = 0.048). Next, we evalu-
ated the prognostic value of BCORL1 expression in HCC
patients through Kaplan-Meier survival analysis. HCC
patients with high expression of BCORL1 had an obviously
reduced 5-year overall survival (OS) as compared with
those with low expression of BCORL1 (P = 0.002, Fig. 2).
Furthermore, it was showed that high expression of
BCORL1 was associated with shorter recurrence-free
survival (RFS) (P = 0.001, Fig. 2). In addition, BCORL1
expression was indicated to be an independent pre-
dictor of 5-year OS and RFS of HCC patients (P = 0.002
and P = 0.003, Table 2) through multivariate Cox re-
gression analysis. Thus, our data demonstrate that
BCORL1 is a potential valuable prognostic indicator for
the prognosis of HCC patients.
BCORL1 promotes cell migration and invasion in HCC cells
To further elucidate the biological function of BCORL1
in HCC, specific siRNAs targeting BCORL1 were used
for loss-of-function experiments in HCCLM3 cells. As
confirmed by Western blot, the expression of BCORL1
protein was significantly down-regulated by BCORL1
siRNA in HCCLM3 cells compared to control cells
(P < 0.05, Fig. 3a and Additional file 1: Figure S1A).
Transwell migration assays were performed to test
the effect of BCORL1 knockdown on tumor cell
migration. BCORL1 knockdown significantly reduced
the migratory ability of HCCLM3 cells (P < 0.05,
Fig. 3b and Additional file 1: Figure S1B). Further-
more, as determined by Transwell invasion assays,
the invasion of HCCLM3 cells was prominently de-
creased after BCORL1 knockdown in HCCLM3 cells
(P < 0.05, Fig. 3b and Additional file 1: Figure S1B).
Similarly, BCORL1 knockdown evidently suppressed
cell migration and invasion in MHCC97H cells (P < 0.05,
respectively). However, BCORL1 knockdown did not evi-
dently influence cell proliferation in both MHCC97H and
HCCLM3 cells as assessed by BrdU incorporation assays
(P = 0.102 and P = 0.120, respectively, Additional file 2:
Figure S2). Next, BCORL1 overexpressing Hep3B cells
were established by lentivirus-mediated transfection and
confirmed by immunoblotting (P < 0.05, Fig. 3c). In con-
trast, BCORL1 overexpression facilitated the migration
and invasion of Hep3B cells (P < 0.05, respectively, Fig. 3d).
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Thus, these results indicate that BCORL1 truly promotes
the metastatic behaviors of HCC cells in vitro.
BCORL1 inversely regulates E-cadherin abundance in HCC
Further studies were performed to disclose the molecular
mechanisms by which BCORL1 promoted HCC cell migra-
tion and invasion. Previous studies reported that BCORL1
acted as a transcriptional corepressor and repressed the
expression of E-cadherin, which was considered as an
EMT-related epithelial marker and inhibited cancer cell mi-
gration and invasion [8, 10]. The expressions of BCORL1
and E-cadherin were further detected by immunohisto-
chemistry in serial sections of 86 HCC cases. Based on the
immunohistochemical score, the immunoreactivity of E-
cadherin and BCORL1 was considered as either negative
(score 0) or positive (scores 1–3). Positive expression of E-
cadherin was detected in 70.0 % (21/30) of the HCC speci-
mens with negative expression of BCORL1, whereas only
35.7 % (20/56) of BCORL1 positively expressing HCC cases
showed a positive E-cadherin signal (P < 0.05, Fig. 4a).
Otherwise, Pearson’s correlation analysis confirmed that
BCORL1 expression was inversely correlated with E-
cadherin in HCC tissues (r = −0.723, P = 0.002, Fig. 4b).
Furthermore, HCCLM3 cells that were transfected with
BCORL1 siRNA or scrambled siRNA were subjected to
qRT-PCR and Western blot for E-cadherin. Our data found
Fig. 2 Prognostic value of BCORL1 for HCC patients. Kaplan-Meier overall survival (OS) and recurrence-free survival (RFS) curves of HCC patients in
accordance with their expression status of BCORL1 protein. High expression of BCORL1 protein conferred a worse 5-year OS and RFS for HCC patients.
The expression of BCORL1 was divided into low level group (n = 43) and high level group (n = 43) based on the cutoff value which was defined as the
median protein level of the 86 HCC samples detected by Western blot
Fig. 1 BCORL1 is abnormally up-regulated in human HCC. a Representative Western blot analysis showed the expression of BCORL1 in the HCC (T)
and matched nontumor tissues (NT). Quantitative analysis indicated that BCORL1 protein was significantly up-regulated in HCC tissues as compared
with that in nontumor tissues. n = 86; *P < 0.05 by t test. b The expression levels of BCORL1 protein in HCC cell lines (HepG2, Hep3B, MHCC97H and
HCCLM3) and a normal hepatic cell line (LO2). n = 3; *P < 0.05 by ANOVA. c The expression levels of E-cadherin mRNA in HCC cell lines and a normal
hepatic cell line. n = 3; *P < 0.05 by ANOVA
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that BCORL1 knockdown resulted in obvious increase of
E-cadherin expression in HCC cells (P < 0.05, respect-
ively, Fig. 4c and 4d). On the contrary, BCORL1 over-
expression significantly reduced E-cadherin expression
in Hep3B cells (P < 0.05, respectively, Fig. 4e and 4f ).
Furthermore, the regulatory effect of BCORL1 on E-
cadherin expression was further confirmed by immuno-
fluorescence (Fig. 5). Interestingly, BCORL1 knockdown
decreased the levels of vimentin and N-cadherin, two
EMT-related mesenchymal markers, in HCCLM3 cells
(P < 0.05, respectively, Fig. 4d), while BCORL1
overexpression increased the expressions of vimentin
and N-cadherin in Hep3B cells (P < 0.05, respectively,
Fig. 4f ), indicating BCORL1 affected EMT in HCC
cells. Thus, BCORL1 inversely regulates E-cadherin
abundance and facilitates EMT in HCC.
Fig. 3 BCORL1 increases migrated and invaded HCC cells. a HCCLM3 cells with BCORL1 siRNA and scrambled siRNA transfection, respectively,
were subjected to immunoblotting for BCORL1. n = 6; *P < 0.05 by t test. b Transwell migration assays showed that BCORL1 knockdown inhibited
cell migration in HCCLM3 cells. As assessed by Transwell invasion assays, HCCLM3 cell invasion was inhibited by BCORL1 knockdown. *P< 0.05 by t test;
n= 3. c Hep3B cells that were infected with BCORL1 or empty vector (EV) lentiviruses, were detected by Western blot. n= 6; *P< 0.05 by t test. d BCORL1
overexpression increased the number of migrated and invaded cells as measured by Transwell assays in Hep3B cells. *P< 0.05 by t test; n= 3
Table 2 Multivariate Cox regression analysis of 5-year OS and RFS of 86 HCC patients
Variables OS RFS
HR 95 % CI P HR 95 % CI P
No. of tumor nodules (1 vs ≥2) 0.736 0.578–0.939 0.014* 0.753 0.588–0.965 0.025*
Venous infiltration (Absent vs Present) 0.812 0.646–1.022 0.076 0.796 0.632–1.004 0.054
TNM tumor stage (I+II vs III+IV) 0.267 0.194–0.367 <0.001* 0.236 0.170–0.328 <0.001*
BCORL1 expression (Low vs High) 0.660 0.509–0.854 0.002* 0.672 0.518–0.872 0.003*
OS overall survival, RFS recurrence-free survival, TNM tumor-node-metastasis, HR hazard ratio, CI confidence interval. *Statistically significant
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BCORL1 promotes the migration and invasion of HCC
cells by suppressing E-cadherin
To validate whether E-cadherin participates in the pro-
moting effects of BCORL1 on HCC cell migration and
invasion, BCORL1 down-regulating HCCLM3 cells were
subsequently transfected with scrambled siRNA or E-
cadherin siRNA. E-cadherin knockdown was confirmed
by Western blot (P < 0.05, Fig. 6a). Transwell assays indi-
cated that E-cadherin knockdown abolished the inhibi-
tory effect of BCORL1 knockdown on the mobility of
HCCLM3 cells, resulting in a significant increase of
migrated and invaded cell numbers (P < 0.05, Fig. 6b).
Fig. 4 BCORL1 is inversely correlated with E-cadherin in HCC. a The positive expression rate of E-cadherin in BCORL1 positive HCC specimens was
significantly lower than that in BCORL1 negative cases. *P< 0.05 by Pearson chi-squared test. b Representative immunohistochemical staining showed
weak staining of E-cadherin (III) in BCORL1 positive-expressing tumor (I) and strong staining of E-cadherin (IV) in BCORL1 negative-expressing tumor (II).
Scale bar: 50 μm. c qRT-PCR analysis of E-cadherin mRNA expression in HCCLM3 cells with BCORL1 siRNA or scrambled siRNA transfection.
*P < 0.05 by t test, n = 3. d BCORL1 knockdown increased the level of E-cadherin protein and reduced the expression of vimentin and
N-cadherin in HCCLM3 cells. *P < 0.05 by t test, n = 6. e qRT-PCR analysis of E-cadherin mRNA expression in Hep3B cells with BCORL1or
empty vector (EV) lentiviruses infection. *P < 0.05 by t test, n = 3. f BCORL1 overexpression decreased the level of E-cadherin protein and
up-regulated the expression of vimentin and N-cadherin in Hep3B cells. *P < 0.05 by t test, n = 6
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Fig. 5 Immunofluorescent staining of E-cadherin in HCC cells. HCC cells that were treated with corresponding vectors were subjected to
immunofluorescence for E-cadherin. BCORL1 knockdown increased E-cadherin immunofluorescence densities in HCCLM3 cells and BCORL1
overexpression reduced the expression of E-cadherin in Hep3B cells. DAPI stain (blue) was used to identify nuclei. Scale bar: 20 μm
Fig. 6 E-cadherin knockdown abolishes the anti-metastatic effect of BCORL1 knockdown. a Scrambled siRNA or E-cadherin siRNA was transfected
into BCORL1 down-regulating HCCLM3 cells and confirmed by Western blot. n = 6; *P < 0.05 by t test. b E-cadherin knockdown increased cell
migration and invasion in BCORL1 down-regulating HCCLM3 cells. n = 3, *P < 0.05 by t test
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Taken together, these results suggest that E-cadherin
probably acts as a downstream factor of BCORL1 and
mediates the contributing effects of BCORL1 on HCC
cell migration and invasion.
Discussion
The expression of BCORL1 was highest in testis and
prostate tissues, medium in lymphocytes and spleen, and
low in many other tissues as demonstrated by Northern
blot assay [10]. Previous study has reported that the ex-
pression of BCORL1-ELF4 chimeric transcript in HCC
tissues is obviously higher than the expression of wild-
type BCORL1 and ELF4 mRNA in noncancerous liver
tissues [11]. However, the expression status of BCORL1
protein in HCC specimens and its clinical significance
are largely unknown. In this study, we initially detected
the expression of BCORL1 protein in HCC tissues and
matched tumor-adjacent tissues. Our data found that
BCORL1 protein in tumor tissues was significantly in-
creased as compared with that in nontumor tissues. Fur-
thermore, elevated expression of BCORL1 protein was
observed in HCC cell lines, especially in those with
highly metastatic ability (HCCLM3 and MHCC97H).
While the expression of E-cadherin mRNA showed an
opposite pattern in HCC cell lines. Clinical association
analysis indicated that high expression of BCORL1 pro-
tein was correlated with poor clinical features of HCC
including multiple tumor nodes, venous infiltration and
advanced TNM tumor stage. These data suggest that
BCORL1 may function as an oncogene and contributes
to tumor metastasis in HCC. Notably, survival analysis
demonstrated that high expression of BCORL1 con-
ferred significant shorter 5-year OS and RFS of HCC
patients. Consistent with our data, patients with up-
regulation of BCORL1 mRNA have a shorter median
overall survival (33.02 months vs control: 45.07 months)
and recurrence-free survival (8.64 months vs control:
19.65 months) in the cBioPortal for Cancer Genomics
data, though the difference had no statistical significance
[17, 18]. Moreover, Multivariate Cox repression analysis
disclosed that BCORL1was an independent predictor of
the prognosis of HCC patients. The mechanism by
which BCORL1 is regulated in cancer is poorly investi-
gated. Data analysis with the gene expression microarray
showed that BCORL1 was a potential target gene of
miR-155 in the azoxymethane (AOM) and dextran
sulfate sodium (DSS) induced colitis-associated colon
cancer mouse model [19]. Thus, it is worth to disclose
the mechanism by which BCORL1 is up-regulated in
HCC. Taken together, our data indicate that BCORL1
expression is important for the survival prediction of
HCC patients.
Mutations of BCORL1 have been found in acute my-
elogenous leukemia, myelodysplastic syndromes and
intracranial germ cell tumours [20–24]. Furthermore,
BCORL1 is a tumor suppressor gene that may be inac-
tivated by mutations in acute myeloid leukemia [21].
While BCORL1 expression is not a predisposing factor
of familial breast cancer [25]. However, studies about
the biological function of BCORL1 in human cancers
are rarely reported. According to our clinical research,
we evaluated the influence of BCORL1 alteration on
the migration and invasion of HCC cells. As expected,
BCORL1 knockdown prominently reduced the migra-
tory and invasive abilities of HCC cells. Otherwise,
BCORL1 overexpression significantly promoted HCC
cell migration and invasion. However, what is the
underlying mechanism involved in the pro-metastatic
role of BCORL1 in HCC? Pagan JK et al. have shown
that BCORL1 mediates the repression of E-cadherin,
which is critical to maintain normal epithelial cell
contact and its downregulation has been seen in the
majority of human cancers including HCC [4, 10, 26].
Decreased expression of E-cadherin is considered as
the initiation of the EMT, which plays important role
in the spread of malignant hepatocytes during HCC
progression [27]. Thus, we investigated the regulatory
effect of BCORL1 on the expression of E-cadherin. In
HCC specimens, the expressions of E-cadherin in
BCORL1 positive cases were prominently lower than
those in BCORL1 negative cases. Furthermore, an
inverse correlation between BCORL1 and E-cadherin
expression in HCC tissues was confirmed by the im-
munohistochemical experiments. Our in vitro studies
demonstrated that BCORL1 knockdown significantly
increased the mRNA and protein levels of E-cadherin
in HCCLM3 cells. On the contrary, BCORL1 overex-
pression reduced E-cadherin expression in Hep3B
cells. Importantly, BCORL1 positively regulated the
abundance of vimentin and N-cadherin, which were
considered as mesenchymal markers in EMT, in HCC
cells. These results indicate that BCORL1 may be a novel
regulator of EMT in HCC. Moreover, E-cadherin knock-
down abrogated BCORL1 deletion-induced suppression of
HCC cell migration and invasion. Since BCORL1 was re-
ported as corepressor on E-cadherin promoter [10]. A
number of transcriptional repressors are known to regu-
late E-cadherin expression, including Snail [28], Slug [29],
Twist [30], and ZEB/δEF1 [31, 32], and it is possible that
BCORL1 might function together with these repressors,
or as part of a separate as yet unknown complex [10].
Thus, these data suggest that BCORL1 may promote the
migratory and metastatic ability of HCC cells by repres-
sing the expression of E-cadherin and subsequently pro-
moting EMT.
In conclusion, this study confirms the overexpression
of BCORL1 in HCC. And increased expression of
BCORL1 is associated with poor prognostic features. We
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demonstrate that BCORL1 expression is an independent
prognostic marker for HCC patients. Our in vitro exper-
iments reveal that BCORL1 promotes the migration and
invasion of HCC cells. Furthermore, BCORL1 inversely
regulates E-cadherin abundance and promotes EMT in
HCC cells. Altogether, deregulation of BCORL1 may
play a fundamental role in tumor metastasis and may
serve as a novel prognostic indicator and potential thera-
peutic target for HCC.
Conclusions
In summary, this study shows that the expression of
BCORL1 is up-regulated in HCC tissues as compared with
that in matched adjacent noncancerous tissues. Further-
more, the relative expression of BCORL1 in HCC cell lines
is significantly higher than that in the normal hepatic cell
line. Clinical association analyses indicate that high expres-
sion of BCORL1 is evidently associated with poor prognos-
tic features of HCC. Notably, BCORL1 expression is an
independent prognostic marker for predicting 5-year OS
and RFS of HCC patients. In vitro studies demonstrate that
BCORL1 knockdown inhibits cell migration and invasion
in HCCLM3 cells. In contrast, BCORL1 overexpression
increases the number of migrated and invaded Hep3B cells.
Interestingly, BCORL1 is inversely correlated with the levels
of E-cadherin in HCC tissues. Otherwise, our data indicate
that BCORL1 inversely regulates the abundance of E-
cadherin and subsequently facilitates EMT in HCC cells.
Importantly, E-cadherin knockdown abrogates the effects
of BCORL1 knockdown on inhibiting HCC cell mobility.
This study reveals that BCORL1 may play a critical role in
the tumor metastasis of HCC by suppressing E-cadherin
and may be a potential prognostic biomarker and thera-
peutic target for HCC.
Additional files
Additional file 1: Figure S1. BCORL1 knockdown inhibits cell migration
and invasion in HCCLM3 cells. A) HCCLM3 cells that were tranfected with
scrambled siRNA or BCORL1 siRNA-1 were subjected to Western blot for
BCORL1. n = 6; *P < 0.05 by t test. B) Transwell migration assays showed
that BCORL1 knockdown inhibited cell migration in HCCLM3 cells. As
assessed by Transwell invasion assays, HCCLM3 cell invasion was inhibited
by BCORL1 knockdown. *P < 0.05 by t test; n = 3. (TIF 1951 kb)
Additional file 2: Figure S2. BCORL1 knockdown does not affect HCC
cell proliferation. HCCLM3 and MHCC97H cells that were transfected with
scramble siRNA or BCORL1 siRNA were subjected to BrdU incorporation
assays. Quantitative data indicated that BCORL1 knockdown did not
significantly influence cell proliferation in both HCCLM3 and MHCC97H
cells. (TIF 72 kb)
Abbreviations
AOM: azoxymethane; BCORL1: BCL6 corepressor-like 1; CtBP: C-terminal-binding
protein; DMEM: Dulbecco’s modified Eagle medium; DSS: dextran sulfate sodium;
ELF4: E74-like factor 4; EMT: Epithelial-mesenchymal transition; HBV: Hepatitis B
virus; HCC: Hepatocellular carcinoma; HRP: Horseradish peroxidase; OS: Overall
survival; qRT-PCR: Quantitative reverse transcription polymerase chain reaction;
RFS: Recurrence-free survival; SDS-PAGE: sodium dodecyl sulfate
polyacrylamide gel electrophoresis; SP-IHC: Streptavidin peroxidase
conjugate-immunohistochemistry; TNM: Tumor-node-metastasis; UICC/
AJCC: International Union Against Cancer/American Joint Committee on
Cancer; ZEB1/2: Zinc finger E-box-binding homeobox 1/2.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
GZY, ZKL, YFW, CWD, CL and WY carried out the cell biology and molecular
biology experiments, participated in the sequence alignment and drafted
the manuscript. YMY, QGL and KST participated in the design of the study
and performed the statistical analysis. QGL and KST conceived of the study,
and participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by the National Natural Science Foundation of
China (grant 81402039, 81272645 and 81572847).
Received: 21 June 2015 Accepted: 10 February 2016
References
1. Gores GJ. Decade in review-hepatocellular carcinoma: HCC-subtypes,
stratification and sorafenib. Nat Rev Gastroenterol Hepatol. 2014;11:645–7.
2. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M.
Hepatitis B and C virus infection and hepatocellular carcinoma in China: a
review of epidemiology and control measures. J Epidemiol. 2011;21:401–16.
3. Tu K, Dou C, Zheng X, Li C, Yang W, Yao Y, Liu Q. Fibulin-5 inhibits
hepatocellular carcinoma cell migration and invasion by down-regulating
matrix metalloproteinase-7 expression. BMC Cancer. 2014;14:938.
4. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life
Sci. 2008;65:3756–88.
5. Canel M, Serrels A, Frame MC, Brunton VG. E-cadherin-integrin crosstalk in
cancer invasion and metastasis. J Cell Sci. 2013;126:393–401.
6. Tu K, Zheng X, Dou C, Li C, Yang W, Yao Y, Liu Q. MicroRNA-130b promotes
cell aggressiveness by inhibiting peroxisome proliferator-activated receptor
gamma in human hepatocellular carcinoma. Int J Mol Sci. 2014;15:20486–99.
7. Zhai X, Zhu H, Wang W, Zhang S, Zhang Y, Mao G. Abnormal expression of
EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with
clinicopathological features and prognosis in HCC. Med Oncol. 2014;31:970.
8. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions.
J Clin Invest. 2009;119:1429–37.
9. Vervoort SJ, Lourenco AR, van Boxtel R, Coffer PJ. SOX4 mediates TGF-
beta-induced expression of mesenchymal markers during mammary cell
epithelial to mesenchymal transition. PLoS One. 2013;8:e53238.
10. Pagan JK, Arnold J, Hanchard KJ, Kumar R, Bruno T, Jones MJ, Richard DJ,
Forrest A, Spurdle A, Verdin E, et al. A novel corepressor, BCoR-L1, represses
transcription through an interaction with CtBP. J Biol Chem. 2007;282:
15248–57.
11. Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, Tsutsumi S,
Sonoda K, Totsuka H, Shirakihara T, et al. High-resolution characterization of
a hepatocellular carcinoma genome. Nat Genet. 2011;43:464–9.
12. Li C, Yang W, Zhang J, Zheng X, Yao Y, Tu K, Liu Q. SREBP-1 has a prognostic
role and contributes to invasion and metastasis in human hepatocellular
carcinoma. Int J Mol Sci. 2014;15:7124–38.
13. Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C, Yao Y, Liu Q. Fbxw7 is an independent
prognostic marker and induces apoptosis and growth arrest by regulating YAP
abundance in hepatocellular carcinoma. Mol Cancer. 2014;13:110.
14. Tu K, Zheng X, Zhou Z, Li C, Zhang J, Gao J, Yao Y, Liu Q. Recombinant human
adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell
lines mediated by p53-Fbxw7 pathway, which controls
c-Myc and cyclin E. PLoS One. 2013;8:e68574.
15. Tu K, Li J, Verma VK, Liu C, Billadeau DD, Lamprecht G, Xiang X, Guo L,
Dhanasekaran R, Roberts LR, et al. Vasodilator-stimulated phosphoprotein
promotes activation of hepatic stellate cells by regulating Rab11-dependent
plasma membrane targeting of transforming growth factor beta receptors.
Hepatology. 2015;61:361–74.
Yin et al. BMC Cancer  (2016) 16:103 Page 10 of 11
16. Tu K, Zheng X, Zan X, Han S, Yao Y, Liu Q. Evaluation of Fbxw7 expression
and its correlation with the expression of c-Myc, cyclin E and p53 in human
hepatocellular carcinoma. Hepatol Res. 2012;42:904–10.
17. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y,
Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer
genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
18. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A,
Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an
open platform for exploring multidimensional cancer genomics data.
Cancer Discov. 2012;2:401–4.
19. Li W, Han W, Zhao X, Wang H. Changes of expression of miR-155 in colitis-
associated colonic carcinogenesis. Zhonghua Zhong Liu Za Zhi. 2014;36:257–62.
20. Li M, Collins R, Jiao Y, Ouillette P, Bixby D, Erba H, Vogelstein B, Kinzler KW,
Papadopoulos N, Malek SN. Somatic mutations in the transcriptional
corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood.
2011;118:5914–7.
21. Tiacci E, Grossmann V, Martelli MP, Kohlmann A, Haferlach T, Falini B. The
corepressors BCOR and BCORL1: two novel players in acute myeloid
leukemia. Haematologica. 2012;97:3–5.
22. Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, Itzykson R,
Sanada M, Shiraishi Y, Gelsi-Boyer V, et al. BCOR and BCORL1 mutations in
myelodysplastic syndromes and related disorders. Blood. 2013;122:3169–77.
23. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF,
Schmidt HK, Yellapantula V, Miller CA, et al. Age-related mutations associated
with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:
1472–8.
24. de Rooij JD, van den Heuvel-Eibrink MM, Hermkens MC, Verboon LJ, Arentsen-
Peters ST, Fornerod M, et al. BCOR and BCORL1 mutations in pediatric Acute
Myeloid Leukemia. Haematologica. 2015;100:e194–5.
25. Lose F, Arnold J, Young DB, Brown CJ, Mann GJ, Pupo GM, Khanna KK,
Chenevix-Trench G, Spurdle AB. BCoR-L1 variation and breast cancer. Breast
Cancer Res. 2007;9:R54.
26. van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members
in cancer. Nat Rev Cancer. 2014;14:121–34.
27. Liu Z, Tu K, Liu Q. Effects of microRNA-30a on migration, invasion and prognosis
of hepatocellular carcinoma. FEBS Lett. 2014;588:3089–97.
28. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG,
Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76–83.
29. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A. The
transcription factor Slug represses E-cadherin expression and induces epithelial
to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell
Sci. 2003;116:499–511.
30. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C,
Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master
regulator of morphogenesis, plays an essential role in tumor metastasis.
Cell. 2004;117:927–39.
31. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E,
Mareel M, Huylebroeck D, van Roy F. The two-handed E box binding zinc
finger protein SIP1 downregulates E-cadherin and induces invasion. Mol
Cell. 2001;7:1267–78.
32. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during
development and carcinogenesis. Int J Dev Biol. 2004;48:365–75.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Yin et al. BMC Cancer  (2016) 16:103 Page 11 of 11
